Organidin

Executive Summary

"Higher sales of expectorant/mucolytic products" also contributed to sales growth, C-W says. Expectorant/mucolytic sales were $54 mil. in the period compared to $34 mil. a year ago. "The unit volume gain in expectorant/mucolytic products was due primarily to a decline in sales of competitive products. The company is unable to determine whether such decline will continue," the report states. Although FDA ordered all marketers of iodinated glycerol products to cease marketing the drugs and to submit NDAs in an April 1993 warning letter, C-W has continued to market Organidin